摘要
目的观察艾司西酞普兰治疗抑郁症的疗效和安全性。方法抑郁症患者297例,分为艾司西酞普兰(20 mg.d-1)组116例,度洛西汀(60 mg.d-1)组105例,帕罗西汀(20 mg.d-1)组76例,疗程6周。于治疗前及治疗1,2,4,6周末采用汉密尔顿抑郁量表(HAMD)17项作为主要指标评价疗效,用不良反应量表(TESS)评定不良反应。结果艾司西酞普兰组、度洛西汀组与帕罗西汀组的有效率分别为81.7%,77.8%及79.4%,三者差异无统计学意义(P>0.05);艾司西酞普兰组的患者中出现恶心不良反应发生率虽然高于其他两组,但差异亦无统计学意义。结论艾司西酞普兰起效迅速,不良反应适中,是一种新型安全的抑郁症治疗物。
Objective To evaluate the efficacy and safety of escitalopram on depressive disorder in comparison with du- loxetine and paroxetine . Methods A total of 297 patients with depressive disorder were divided into three groups： 116 cases in escitalopram group （20 mg·d-1）, 105 cases in duloxetine group （60 mg · d-1） and 76 cases in paroxetine group （20 mg ·d-1 ）. All of the patients treated for 6 weeks. The main efficacy was evaluated by 17 items on Hamilton Depression Scale （HAMD） at baseline and the end of 1,2, 4,and 6 weeks after therapy. Moreover, the adverse effects were assessed with treatment emergent symptom scale （TESS）. Results The efficacy of the three drugs was 81.7% （escitalopram）, 77.8% （duloxetine） and 79.4% （paroxetine）, respectively, with showed no significant difference. The incidence of adverse reaction in the escitalopram group was higher than that of the other two groups, presenting no statistical significance. Conclusion Escita- lopram is a new-generation drug for depression with rapid onset of action and moderate adverse reaction.
出处
《医药导报》
CAS
北大核心
2013年第3期331-334,共4页
Herald of Medicine
